1. Home
  2. UNTY vs DMAC Comparison

UNTY vs DMAC Comparison

Compare UNTY & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Unity Bancorp Inc.

UNTY

Unity Bancorp Inc.

HOLD

Current Price

$53.96

Market Cap

523.6M

Sector

Finance

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$7.93

Market Cap

428.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UNTY
DMAC
Founded
1991
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
523.6M
428.6M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
UNTY
DMAC
Price
$53.96
$7.93
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$65.00
$15.50
AVG Volume (30 Days)
46.8K
251.4K
Earning Date
01-13-2026
03-16-2026
Dividend Yield
1.11%
N/A
EPS Growth
39.66
N/A
EPS
5.67
N/A
Revenue
$127,871,000.00
N/A
Revenue This Year
$11.57
N/A
Revenue Next Year
$8.52
N/A
P/E Ratio
$9.52
N/A
Revenue Growth
23.99
N/A
52 Week Low
$36.65
$3.19
52 Week High
$57.24
$10.42

Technical Indicators

Market Signals
Indicator
UNTY
DMAC
Relative Strength Index (RSI) 54.73 45.00
Support Level $51.31 $7.17
Resistance Level $53.11 $9.00
Average True Range (ATR) 1.71 0.58
MACD -0.09 -0.00
Stochastic Oscillator 53.05 41.53

Price Performance

Historical Comparison
UNTY
DMAC

About UNTY Unity Bancorp Inc.

Unity Bancorp Inc is a bank holding company that serves as a holding company for Unity Bank. It conducts a traditional and community-oriented commercial banking business and offers services, including personal and business checking accounts, time deposits, money market accounts, regular savings accounts, and others. The company structures its specific services and charges in a manner designed to attract the business of small and medium-sized businesses and professional communities, as well as individuals residing, working, and shopping in its service area. The company engages in a wide range of lending activities and offers commercial, Small Business Administration, consumer, mortgage, home equity, and personal loans.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: